No Data
No Data
Oriental Wealth (300059.SZ) plans to distribute 0.4 yuan for 10 shares as dividends on April 23
Oriental Wealth (300059.SZ) announced that the company's 2023 equity distribution plan: 0.4 yuan for every 10 shares...
Oriental Wealth (300059.SZ): Oriental Wealth Securities is eligible for underwriting and sponsorship business
Gelonghui, April 16 | Oriental Wealth (300059.SZ) said on the investor interactive platform that Dongfang Wealth Securities is eligible for underwriting and sponsorship business.
Jefferies Adjusts East Money Information's Price Target to 17.60 Yuan From 19.70 Yuan, Keeps at Buy
East Money Information (SHE:300059) has an average rating of outperform and price targets ranging from 9.96 yuan to 30.48 yuan, according to analysts polled by CapitalIQ. Price (RMB): ¥13.97, Change:
Revenue Miss: East Money Information Co.,Ltd. Fell 9.2% Short Of Analyst Revenue Estimates And Analysts Have Been Revising Their Models
East Money Information Co.,Ltd. (SZSE:300059) just released its latest full-year report and things are not looking great. East Money InformationLtd missed analyst forecasts, with revenues of CN¥1
Gelonghui Announcements Selected | Oriental Wealth: Net profit for 2023 fell 3.71% to 8.193 billion yuan, and plans to distribute 10 to 0.4 yuan; Shouyao Holdings: Core self-developed products are all in the R&D stage, and no products have been launched t
[Hot Focus] First Pharmaceutical Holdings (688197.SH): The core self-developed products are all in the development stage. No products have been launched to contribute sales revenue. First Pharmaceutical Holdings (688197.SH) announced abnormal stock trading fluctuations. The company's daily operations are all normal, and every effort is being made to promote registered clinical research on the core pipeline. As of the disclosure date of this announcement, the core self-developed product SY-707 is undergoing pre-NDA communication based on registered clinical phase III trial results; the third-generation ALK inhibitor SY-3505 is undergoing NSCLC critical phase II trials against second-generation ALK inhibitor treatment failure
Oriental Wealth (300059.SZ) plans to launch the 2024 Restricted Stock Incentive Plan with a grant price of 13.75 yuan/share
Oriental Wealth (300059.SZ) released the 2024 Restricted Stock Incentive Plan (Draft). This incentive plan...
No Data